A new industry analysis argues that GLP-1 uptake is moving beyond proof of weight loss and into a broader evidence-and-delivery challenge for pharma, payers, and primary care. The piece highlights that regulators have already expanded GLP-1 indications into cardiovascular risk reduction, MASH, and sleep apnea, but real-world systems must support longer-term chronic use. The report emphasizes three operational tests for companies: showing benefits beyond weight loss, building care infrastructure that can manage patients for years, and earning trust amid a fast-moving market with expanding drug classes. It also flags payer affordability and coverage uncertainty, along with the limited clinical backup available in primary care settings. The analysis suggests the next wave—triple agonists, amylin-based combinations, and oral formulations—will further raise complexity by adding more populations and evidence requirements.